STRM.BIO to Present Preclinical Data on a Novel Bone Marrow/HSC-Targeted, Megakaryocyte-Derived Extracellular Vesicle Delivery Platform for In Vivo Gene Therapy at ASH 2023
/PRNewswire/ -- STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and...